While, it has been reported that inhibition of plasma CETP by apoC-I is blunted in CHD patients with dyslipidemia, this is probably due to increasing amounts of VLDL-bound apoC-I, which is inactive as a CETP inhibitor[52]. This evidence concerns the gene CETP and coronary artery disorder.